KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Operating Leases (2018 - 2025)

Moderna (MRNA) has disclosed Operating Leases for 8 consecutive years, with $653.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 2.68% to $653.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $653.0 million through Dec 2025, down 2.68% year-over-year, with the annual reading at $653.0 million for FY2025, 2.68% down from the prior year.
  • Operating Leases for Q4 2025 was $653.0 million at Moderna, down from $660.0 million in the prior quarter.
  • The five-year high for Operating Leases was $697.0 million in Q3 2023, with the low at $79.0 million in Q3 2022.
  • Average Operating Leases over 5 years is $384.8 million, with a median of $385.0 million recorded in 2021.
  • The sharpest move saw Operating Leases crashed 37.8% in 2022, then surged 782.28% in 2023.
  • Over 5 years, Operating Leases stood at $106.0 million in 2021, then decreased by 13.21% to $92.0 million in 2022, then skyrocketed by 598.91% to $643.0 million in 2023, then increased by 4.35% to $671.0 million in 2024, then decreased by 2.68% to $653.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $653.0 million, $660.0 million, and $666.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.